Clinical Trials Logo
  1. Home
  2. Antiplatelet Therapy
  3. NCT03758248

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

Antiplatelet Therapy Clinical Trial

Official title:
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

Clinical Trial Summary

Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some patients develop bleeding event because of the improper dosage and covariation. This observational study is designed for clarifying the Influence of gene polymorphism on clinical outcomes in patients undergoing PCI.

Clinical Trial Description

Patients undergoing PCI who received dual antiplatelet therapy with both aspirin (100mg) and P2Y12 inhibitors in standard dosage were enrolled. Investigators examined plasma biomarkers for platelet activation and DNA in those patients, and then analyzed the CYP2C19 genetic polymorphism to examine the influence of this genetic variation on the several biomarkers for platelet activation and bleeding event. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03758248
Study type Observational [Patient Registry]
Source Beijing Anzhen Hospital
Contact Yujie Zhou, PhD,MD
Phone 8613901330652
Email azzyj12@163.com
Status Recruiting
Phase
Start date December 1, 2018
Completion date September 30, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT01231035 - REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS) N/A
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01144819 - Platelet Inhibition in the Acute Phase of STEMI N/A
Completed NCT03039205 - Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor Phase 2
Recruiting NCT04624295 - Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs) Phase 4
Recruiting NCT05554822 - Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study Phase 3
Recruiting NCT02099422 - Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome N/A
Not yet recruiting NCT04060914 - LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention Phase 4
Terminated NCT03224923 - A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY) Phase 4
Completed NCT03987373 - DACAB Trial: Follow-up Extension